NIP
PRTK

Nicholas Investment Partners’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Nicholas Investment Partners’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-204,009
Closed -$4.92M – 279
2017
Q2 		$4.92M Buy
204,009
+173,717
+573% +$3.84M 0.35% 89
2017
Q1 		$583K Buy
+30,292
New +$477K 0.04% 249

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
ECP
Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Nicholas Investment Partners's PRTK Position: Q3 2017 in Review

Nicholas Investment Partners sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2017, closing a stake of 204,009 shares — an estimated $4.92M sold.

Nicholas Investment Partners first reported a position in PRTK in Q1 2017 and held it in 2 quarters. The position peaked at $4.92M in Q2 2017. 133 funds tracked by Wall St. Rank hold PRTK as of Q3 2017.

  • Nicholas Investment Partners reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Nicholas Investment Partners sold 204,009 Paratek Pharmaceuticals, Inc. shares in Q3 2017, an estimated $4.92M.
  • Nicholas Investment Partners first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
  • Nicholas Investment Partners's Paratek Pharmaceuticals, Inc. position peaked at $4.92M in Q2 2017.
  • 133 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2017.

Based on Nicholas Investment Partners's 13F filing for Q3 2017, filed 13 Nov 2017.